Executive Function
Conditions
Interventions
This is a randomized, controlled, blinded clinical trial involving participants aged 60 or older. Individuals will be randomly assigned to experimental groups in a 1:1 ratio, using opaque, sealed enve
Sponsors
Universidade Federal de Juiz de Fora
Universidade Federal de Juiz de Fora, campus Governador Valadares
Eligibility
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals aged 60 years or older; of both sexes
Exclusion criteria
Exclusion criteria: Participants who have a medical diagnosis of psychological disorders (T.), for example: Social phobia; Bipolar disorder; Autism spectrum disorder (ASD); Personality disorder; Psychotic disorder; and Panic disorder. Neurodegenerative diseases, for example: Alzheimer's; Dementia; Parkinson's; Down syndrome; Multiple sclerosis; Autoimmune rheumatic disease; Hydrocephalus; Epilepsy; and Alcohol and/or illicit drug abuse. Cardiometabolic diseases, for example: Diabetes mellitus (type 1); Coronary artery disease; Stroke; and Chronic kidney disease. Lung diseases, for example: Chronic obstructive pulmonary disease; Pneumonia; Tuberculosis; and Bronchitis. Presenting symptoms suggestive of cardiovascular disease, such as: Syncope; Dyspnea; Tachycardia; and Angina. Presenting symptoms suggestive of neurodegenerative diseases, such as: persistent memory loss of recent events or important information; deficits in speech fluency or sentence construction; difficulty solving everyday problems or making simple decisions; difficulty recognizing people, objects, or places; irritability or aggression without apparent cause; difficulty performing simple motor tasks; loss of coordination and balance without apparent cause. Continuous use of psychotropic medications, such as antidepressants, anxiolytics, mood stabilizers, and/or stimulants, for a period of less than three months, an interval considered necessary for the body to adapt and minimize the initial effects of these medications. Introducing, throughout the intervention protocol, complementary therapies not initially planned, such as psychological and/or psychiatric interventions; use of medications that may influence the outcomes of interest; and the practice of physical or digital exercises that may impact the variables analyzed. Possess psychological or cognitive limitations; and/or osteoarticular conditions that prevent the practice of physical activity (PA) and/or medical impediment to the practice of PA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: It is expected to observe an improvement in cognitive functions (attention, memory, language, naming, abstraction, delayed recall, orientation) and executive functions, measured by the Montreal Cognitive Assessment (MoCA) and the Trail Making Test (TMT), respectively, after eight weeks of intervention, compared to baseline values and the other groups;It is expected to observe an improvement in psychological parameters (anxiety, depression and quality of life), measured using the Beck Anxiety Inventory, Beck Depression Inventory and Quality of Life Questionnaire (SF-36), respectively, after eight weeks of intervention, compared to baseline values and the other groups;Expected outcome 3: It is expected to observe an improvement in functional parameters (aerobic capacity, muscular strength, flexibility, agility and dynamic balance), measured through the Senior Fitness Test (SFT), after eight weeks of intervention, compared to baseline values and the other groups | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactPedro Ian Gualberto
Universidade Federal de Juiz de Fora, campus Governador Valadares
Outcome results
None listed